Resultados de la búsqueda 451-460 of 9198 for Drug-resistant TB
ABBV-383 is an investigational drug being developed for the treatment of R/R Multiple Myeloma (MM). This study includes 2 parts; step-up dose optimization ...
All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...
... of these marrow disorders, but also the changes that occur to render these disorders resistant to therapy. These activities are a first step toward ...
The objectives are to describe the practice patterns of therapeutic agents for treatment of ... resistant prostate cancer (mCRPC) who have ... Testing The Addition ...
Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with ...
The purpose of this study, as a proof-of-concept, is to investigate whether ex vivo fluorescence microscopy can provide adequate visualization of cutaneous ...
... of life improvements after operative management of ... resistant prostate cancer (mCRPC) who have ... The purpose of this study is to learn if the study drug ...
Post Approval Study For Treatment Of Drug-resistant Adult Primary FSGS Using The LIPOSORBER® LA-15 System. Jacksonville, Fla., Rochester, Minn., Scottsdale ...
Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma. Durvalumab is FDA approved for treatment in lung ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?